DB05249InvestigationalSmall molecule
FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
- Mechanism
- Curator reviewed
It is designed to stimulate a patient's immune system to mount a specific and sustained response to disease. FavId is currently being developed for use following treatment with existing standards of care to extend time to disease progression in patients with B-cell non-Hodgkin's lymphoma
- Primary indication
- B-cell non-Hodgkin's lymphomaCurator reviewed
Resolves to
Targets
What you can answer from here — as of April 23, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with FavId, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account